Browsing Tag
Radiopharmaceuticals
24 posts
Is Aptamer Group (LON: APTA) finally seeing sustained pharma traction with its Optimer platform?
Aptamer Group grows FY26 contracts to £1.95M with pharma repeat wins. Find out how its IP-heavy Optimer platform is gaining commercial traction.
Radiopharm Theranostics begins third-cohort enrolment in Phase 1 177Lu-RAD204 trial targeting PD-L1 tumours
Find out how Radiopharm Theranostics is advancing 177Lu-RAD204 in PD-L1-positive tumours as it begins third-cohort enrolment in its Phase 1 trial.
Radiopharm Theranostics (ASX: RAD) begins third cohort in PD-L1 trial—could 177Lu-RAD204 be a game-changer?
Radiopharm Theranostics moves to third cohort in PD-L1 trial with 90mCi dose approval. Explore what this means for its radiopharmaceutical ambitions.
Why Medicines Discovery Catapult and Crown Bioscience think their partnership will change oncology R&D
Discover how Medicines Discovery Catapult and Crown Bioscience are reshaping radiopharmaceutical drug discovery with a new integrated platform.
EMA clears Curasight’s uTREAT trial—will targeted radiopharma redefine brain cancer therapy?
Curasight wins EMA approval for its first uTREAT clinical trial in glioblastoma. Find out how its theranostic strategy could change brain cancer treatment.
Telix Pharmaceuticals gains U.S. Medicare reimbursement code for Gozellix prostate cancer imaging agent
Telix Pharmaceuticals’ Gozellix secures U.S. reimbursement code, opening access to PSMA-PET prostate cancer imaging. Find out what’s next for its rollout and impact.
Mirion Medical showcases advanced radiopharma safety and dosimetry systems at SNMMI 2025 in New Orleans
Mirion Medical unveils new radiation safety and workflow tools for radiopharma and theranostics at SNMMI 2025. Explore their latest innovations.
GE HealthCare unveils LesionID Pro and precision oncology suite to drive AI-led theranostics at SNMMI 2025
GE HealthCare launches LesionID Pro, Omni Legend, and MINItrace Magni at SNMMI 2025 to power AI-led theranostics and whole-body tumor imaging.
Mirion highlights full-spectrum nuclear medicine tools at SNMMI 2025 in New Orleans
Mirion Medical to showcase new dosimetry devices, radiopharmaceutical software, and safety tools at SNMMI 2025, reflecting broader sector convergence.
AtomVie Global Radiopharma partnering with TerraPower Isotopes to secure actinium-225 for global cancer therapy development
AtomVie Global Radiopharma signs agreement with TerraPower Isotopes to secure actinium-225 supply, aiming to advance CDMO-based cancer radiotherapies.